Nomura Holdings’s Iovance Biotherapeutics IOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-26,500
Closed -$196K 2048
2024
Q4
$196K Sell
26,500
-35,189
-57% -$326K ﹤0.01% 2054
2024
Q3
$579K Buy
61,689
+47,514
+335% +$450K ﹤0.01% 1232
2024
Q2
$114K Sell
14,175
-3,940
-22% -$42.2K ﹤0.01% 1680
2024
Q1
$268K Sell
18,115
-39,692
-69% -$462K ﹤0.01% 1390
2023
Q4
$470K Sell
57,807
-11,752
-17% -$61.5K ﹤0.01% 1365
2023
Q3
$316K Sell
69,559
-186,500
-73% -$1.22M ﹤0.01% 1190
2023
Q2
$1.8M Sell
256,059
-115,000
-31% -$823K ﹤0.01% 743
2023
Q1
$2.27M Sell
371,059
-644,679
-63% -$4.45M 0.01% 779
2022
Q4
$6.48M Buy
1,015,738
+34,454
+4% +$269K 0.03% 414
2022
Q3
$9.4M Sell
981,284
-168,117
-15% -$1.94M 0.04% 366
2022
Q2
$13.2M Buy
+1,149,401
New +$15.1M 0.05% 267
2021
Q2
Sell
-12,000
Closed -$380K 2168
2021
Q1
$380K Buy
+12,000
New +$497K ﹤0.01% 1447
2020
Q3
Sell
-10,000
Closed -$275K 1368
2020
Q2
$275K Buy
+10,000
New +$329K ﹤0.01% 963
2019
Q2
Sell
-91,392
Closed -$891K 1209
2019
Q1
$891K Buy
91,392
+30,512
+50% +$296K ﹤0.01% 832
2018
Q4
$538K Buy
+60,880
New +$587K ﹤0.01% 957

Other funds holding IOVA

Nomura Holdings's IOVA Position: Q1 2025 in Review

Nomura Holdings sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 26,500 shares — an estimated $196K sold.

Nomura Holdings first reported a position in IOVA in Q4 2018 and held it in 15 quarters. The position peaked at $13.2M in Q2 2022. 302 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Nomura Holdings reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Nomura Holdings sold 26,500 Iovance Biotherapeutics shares in Q1 2025, an estimated $196K.
  • Nomura Holdings first reported a position in Iovance Biotherapeutics in Q4 2018 and held it in 15 quarters.
  • Nomura Holdings's Iovance Biotherapeutics position peaked at $13.2M in Q2 2022.
  • 302 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Nomura Holdings's 13F filing for Q1 2025, filed 15 May 2025.